Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

GSK Investigational Site, Brussels

GSK Investigational Site, Liège

GSK Investigational Site, New York

GSK Investigational Site, The Bronx

GSK Investigational Site, Valhalla

GSK Investigational Site, Stony Brook

GSK Investigational Site, Washington D.C.

GSK Investigational Site, Washington D.C.

GSK Investigational Site, Monza

GSK Investigational Site, Milan

GSK Investigational Site, Chapel Hill

GSK Investigational Site, Charlotte

GSK Investigational Site, Orlando

GSK Investigational Site, Fort Lauderdale

GSK Investigational Site, Fort Lauderdale

GSK Investigational Site, Ft. Pierce

GSK Investigational Site, Birmingham

GSK Investigational Site, Kansas City

GSK Investigational Site, Dallas

GSK Investigational Site, Longview

GSK Investigational Site, Fort Worth

GSK Investigational Site, Austin

GSK Investigational Site, Phoenix

GSK Investigational Site, Santa Fe

GSK Investigational Site, Los Angeles

GSK Investigational Site, Beverly Hills

GSK Investigational Site, Long Beach

GSK Investigational Site, Bakersfield

GSK Investigational Site, Fresno

GSK Investigational Site, San Francisco

GSK Investigational Site, Portland

GSK Investigational Site, Constanța

GSK Investigational Site, Springfield

GSK Investigational Site, Hillsborough

GSK Investigational Site, Newark

GSK Investigational Site, Toronto

GSK Investigational Site, Montreal

GSK Investigational Site, Montreal

GSK Investigational Site, Montreal

GSK Investigational Site, Bucharest

GSK Investigational Site, Bucharest